[
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-16 11:39:59",
    "publisher": "Proactive Investors",
    "title": "Johnson & Johnson likely to post dip in 4Q earnings",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-likely-to-post-dip-in-4q-earnings-20240116.jpg",
    "site": "proactiveinvestors.com",
    "text": "Johnson & Johnson (NYSE:JNJ) raised its full-year guidance after a strong third quarter which saw earnings beat expectations and its product pipeline advance. Still, Wall Street expects the New Brunswick, New Jersey-based pharmaceutical giant to post a dip in earnings when it reports back for the fourth quarter next Tuesday.",
    "url": "https://www.proactiveinvestors.com/companies/news/1038533?SNAPI",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-16T11:39:59-05:00",
    "date_et": "2024-01-16"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-16 10:20:55",
    "publisher": "Seeking Alpha",
    "title": "Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off?",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-is-the-dividend-still-safe-after-the-20240116.jpg",
    "site": "seekingalpha.com",
    "text": "JNJ stock occupies a top spot in many portfolios due to its consistent performance and low volatility. But should we really and readily accept JNJ as a SWAN stock? A fresh look at Johnson & Johnson is warranted, especially in light of the split-off of its Consumer Health segment (Kenvue stock) and amid the ongoing talc litigation. I share my view on JNJ's two remaining segments, their future prospects, and the decline in cash flow due to the split-off of the Consumer Health segment.",
    "url": "https://seekingalpha.com/article/4663070-johnson-and-johnson-stock-is-dividend-still-safe-after-kenvue-split-off",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-16T10:20:55-05:00",
    "date_et": "2024-01-16"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-17 12:04:45",
    "publisher": "InvestorPlace",
    "title": "7 Mighty Healthcare Stocks Changing the Game of Medicine",
    "image": "https://images.financialmodelingprep.com/news/7-mighty-healthcare-stocks-changing-the-game-of-medicine-20240117.jpg",
    "site": "investorplace.com",
    "text": "With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from permanent relevance.",
    "url": "https://investorplace.com/2024/01/7-mighty-healthcare-stocks-changing-the-game-of-medicine/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-17T12:04:45-05:00",
    "date_et": "2024-01-17"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-18 14:17:40",
    "publisher": "InvestorPlace",
    "title": "7 Must-Have Stocks for Serious Wealth Accumulation",
    "image": "https://images.financialmodelingprep.com/news/7-musthave-stocks-for-serious-wealth-accumulation-20240118.jpg",
    "site": "investorplace.com",
    "text": "Certain stocks stand out as stalwarts in finance and commerce, charting a course toward serious wealth accumulation. The strategies of these seven companies reveal a tapestry of edgy leadership.",
    "url": "https://investorplace.com/2024/01/7-must-have-stocks-for-serious-wealth-accumulation/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-18T14:17:40-05:00",
    "date_et": "2024-01-18"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-18 14:00:17",
    "publisher": "Zacks Investment Research",
    "title": "Wall Street's Insights Into Key Metrics Ahead of Johnson & Johnson (JNJ) Q4 Earnings",
    "image": "https://images.financialmodelingprep.com/news/wall-streets-insights-into-key-metrics-ahead-of-johnson-20240118.jpg",
    "site": "zacks.com",
    "text": "Get a deeper insight into the potential performance of Johnson & Johnson (JNJ) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.",
    "url": "https://www.zacks.com/stock/news/2212378/wall-street-s-insights-into-key-metrics-ahead-of-johnson-johnson-jnj-q4-earnings?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2212378",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-18T14:00:17-05:00",
    "date_et": "2024-01-18"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-19 17:51:04",
    "publisher": "Zacks Investment Research",
    "title": "Q4 Earnings Results Reflect Stability",
    "image": "https://images.financialmodelingprep.com/news/q4-earnings-results-reflect-stability-20240119.jpg",
    "site": "zacks.com",
    "text": "The picture emerging from the Q4 earnings season thus far has been good enough - not great, but definitely not bad either. Next week, we shift into a much higher gear, with 71 S&P 500 members scheduled to report.",
    "url": "https://www.zacks.com/commentary/2213047/q4-earnings-results-reflect-stability?cid=CS-STOCKNEWSAPI-FT-earnings_preview-2213047",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-19T17:51:04-05:00",
    "date_et": "2024-01-19"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-19 17:17:34",
    "publisher": "Seeking Alpha",
    "title": "2 Dividend Kings For A Potentially Comfortable Retirement",
    "image": "https://images.financialmodelingprep.com/news/2-dividend-kings-for-a-potentially-comfortable-retirement-20240119.jpg",
    "site": "seekingalpha.com",
    "text": "Procter & Gamble and Johnson & Johnson are Dividend Kings with impressive dividend growth track records. Both companies have strong revenue growth prospects and solid free cash flow coverage of their dividends.",
    "url": "https://seekingalpha.com/article/4663844-2-dividend-kings-for-a-comfortable-retirement",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-19T17:17:34-05:00",
    "date_et": "2024-01-19"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-19 09:10:28",
    "publisher": "24/7 Wall Street",
    "title": "5 Dividend Aristocrats That Are Also Wall Street Top Stock Ideas For 2024",
    "image": "https://images.financialmodelingprep.com/news/5-dividend-aristocrats-that-are-also-wall-street-top-20240119.jpg",
    "site": "247wallst.com",
    "text": "This integrated giant is a safer way for investors looking to get positioned in the energy sector and pays a rich 4.10% dividend.",
    "url": "https://247wallst.com/investing/2024/01/19/5-dividend-aristocrats-that-are-also-wall-street-top-stock-ideas-for-2024/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-19T09:10:28-05:00",
    "date_et": "2024-01-19"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-19 08:41:10",
    "publisher": "Zacks Investment Research",
    "title": "J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?",
    "image": "https://images.financialmodelingprep.com/news/jj-jnj-gears-up-to-report-q4-earnings-whats-20240119.jpg",
    "site": "zacks.com",
    "text": "J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.",
    "url": "https://www.zacks.com/stock/news/2212628/j-j-jnj-gears-up-to-report-q4-earnings-what-s-in-store?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview-2212628",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-19T08:41:10-05:00",
    "date_et": "2024-01-19"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-21 11:51:00",
    "publisher": "The Motley Fool",
    "title": "Nearing Retirement? These Stocks Are as Safe as They Come",
    "image": "https://images.financialmodelingprep.com/news/nearing-retirement-these-stocks-are-as-safe-as-they-20240121.jpg",
    "site": "fool.com",
    "text": "Johnson & Johnson is a healthcare giant that has increased its dividend for 61 consecutive years. Lowe's Companies has solid long-term prospects as the second-largest home improvement retailer.",
    "url": "https://www.fool.com/investing/2024/01/21/nearing-retirement-these-stocks-are-as-safe-as-the/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-21T11:51:00-05:00",
    "date_et": "2024-01-21"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-21 10:45:00",
    "publisher": "The Motley Fool",
    "title": "Walgreens Boots Alliance Just Cut Its Dividend: Here Are 2 Companies That Won't",
    "image": "https://images.financialmodelingprep.com/news/walgreens-boots-alliance-just-cut-its-dividend-here-are-20240121.jpg",
    "site": "fool.com",
    "text": "Walgreens Boots Alliance disappointed investors with its recent dividend cut. There are other, more solid companies investors can rely on to pay a dividend.",
    "url": "https://www.fool.com/investing/2024/01/21/walgreens-boots-alliance-just-cut-its-dividend-her/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-21T10:45:00-05:00",
    "date_et": "2024-01-21"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-21 08:14:59",
    "publisher": "Seeking Alpha",
    "title": "2 Ideal Barron's/Fortune New-Year 2024 Dividend Buys",
    "image": "https://images.financialmodelingprep.com/news/2-ideal-barronsfortune-newyear-2024-dividend-buys-20240121.jpg",
    "site": "seekingalpha.com",
    "text": "Barron's 10 favorite Stocks for 2024 came-out 1/17/24. Their New-Year Roundtable, published 1/11/24, listed 8 stocks of note for 2024 and mentioned 15 more. Fortune published their 13 inflation-proof list. Barron's interviews of eleven financial industry Roundtable pros tapped 8 predictions with 15 stocks mentioned. Three stocks made more than one list: Microsoft, Nvidia, Google. Nevertheless, the combined Barron's/Fortune list tracked-by YCharts as of 1/17/24 projected ten-top analyst-estimated net-gains from WTFC, PEP, JPM, ORCL, NVDA, GOLD, KMI, CVX, XOM and topped-by BABA ranging 14% to 70%.",
    "url": "https://seekingalpha.com/article/4664038-2-ideal-barronsfortune-new-year-2024-dividend-buys",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-21T08:14:59-05:00",
    "date_et": "2024-01-21"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-21 06:17:00",
    "publisher": "The Motley Fool",
    "title": "My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024",
    "image": "https://images.financialmodelingprep.com/news/my-5-top-dividend-stocks-to-buy-hand-over-20240121.jpg",
    "site": "fool.com",
    "text": "These companies have a track record of dividend growth and plan to keep that momentum going. Dividends could bolster your portfolio during tough times and multiply your winnings when the market is soaring.",
    "url": "https://www.fool.com/investing/2024/01/21/my-5-top-dividend-stocks-to-buy-in-2024/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-21T06:17:00-05:00",
    "date_et": "2024-01-21"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-22 07:31:06",
    "publisher": "MarketBeat",
    "title": "3 undervalued stocks: Is now the right time to buy?",
    "image": "https://images.financialmodelingprep.com/news/3-undervalued-stocks-is-now-the-right-time-to-20240122.jpg",
    "site": "marketbeat.com",
    "text": "For savvy investors, hunting down undervalued stocks can mean unearthing overlooked stocks with big potential. In any market cycle, undervalued stocks are there, waiting to be scooped up at bargain prices, but they tend to get even less attention in a bull market, as we saw in 2023.",
    "url": "https://www.marketbeat.com/originals/3-undervalued-stocks-is-now-the-right-time-to-buy/?utm_source=snapi",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-22T07:31:06-05:00",
    "date_et": "2024-01-22"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 21:20:42",
    "publisher": "PYMNTS",
    "title": "J&J Sees Surge in MedTech Sales Post-Kenvue Split",
    "image": "https://images.financialmodelingprep.com/news/jj-sees-surge-in-medtech-sales-postkenvue-split-20240123.jpg",
    "site": "pymnts.com",
    "text": "Six months after parting ways with its consumer health unit, Kenvue, Johnson & Johnson has reported total sales of $21.4 billion for the last quarter of 2023, a 7.3% increase from the corresponding quarter in 2022.  The pharmaceutical giant disclosed a net income of $4.13 billion, a rise from the $3.",
    "url": "https://www.pymnts.com/healthcare/2024/jj-sees-surge-in-medtech-sales-post-kenvue-split/?utm_source=snapi",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T21:20:42-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 16:16:03",
    "publisher": "Zacks Investment Research",
    "title": "3 Stocks to Consider After Beating Earnings Estimates",
    "image": "https://images.financialmodelingprep.com/news/3-stocks-to-consider-after-beating-earnings-estimates-20240123.jpg",
    "site": "zacks.com",
    "text": "With the earnings season now in full force, valuable data to gauge the broader economy will be rolling in.",
    "url": "https://www.zacks.com/commentary/2214526/3-stocks-to-consider-after-beating-earnings-estimates?cid=CS-STOCKNEWSAPI-FT-investment_ideas-2214526",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T16:16:03-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 15:21:14",
    "publisher": "Proactive Investors",
    "title": "J&J's Spravato success confirms commercial viability of psychedelics for mental health",
    "image": "https://images.financialmodelingprep.com/news/jjs-spravato-success-confirms-commercial-viability-of-psychedelics-for-20240123.jpg",
    "site": "proactiveinvestors.com",
    "text": "The commercial success of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato for use in treatment-resistant depression and major depressive disorder with suicidal ideation bodes well for other psychedelics companies, analysts at Jefferies believe.  When reporting its 4Q results Tuesday, J&J said Spravato sales grew 73% year-over-year to $206 million, implying an $825 million run rate since the product launched five years ago.",
    "url": "https://www.proactiveinvestors.com/companies/news/1039186?SNAPI",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T15:21:14-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 13:59:18",
    "publisher": "CNBC",
    "title": "Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-settle-talc-baby-powder-investigation-will-20240123.jpeg",
    "site": "cnbc.com",
    "text": "The settlement does not resolve the tens of thousands of lawsuits alleging that J&J's talc-based products caused cancer.",
    "url": "https://www.cnbc.com/2024/01/23/johnson-johnson-to-settle-talc-baby-powder-probe.html",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T13:59:18-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 13:14:12",
    "publisher": "Seeking Alpha",
    "title": "Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q4-2023-earnings-call-transcript-20240123.jpg",
    "site": "seekingalpha.com",
    "text": "Johnson & Johnson (JNJ) Q4 2023 Earnings Call Transcript",
    "url": "https://seekingalpha.com/article/4664456-johnson-and-johnson-jnj-q4-2023-earnings-call-transcript",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T13:14:12-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 12:41:11",
    "publisher": "The Motley Fool",
    "title": "Why Johnson & Johnson Stock Was Pulling Back Today",
    "image": "https://images.financialmodelingprep.com/news/why-johnson-johnson-stock-was-pulling-back-today-20240123.jpg",
    "site": "fool.com",
    "text": "Johnson & Johnson edged out estimates and delivered in-line guidance for 2024. Concerns about legal settlements and competition for drug Stelara seemed to weigh on the stock.",
    "url": "https://www.fool.com/investing/2024/01/23/why-johnson-johnson-stock-was-pulling-back-today/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T12:41:11-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 12:06:31",
    "publisher": "Zacks Investment Research",
    "title": "J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales",
    "image": "https://images.financialmodelingprep.com/news/jjs-jnj-q4-earnings-beat-darzalex-stelara-drive-sales-20240123.jpg",
    "site": "zacks.com",
    "text": "J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.",
    "url": "https://www.zacks.com/stock/news/2214342/j-j-s-jnj-q4-earnings-beat-darzalex-stelara-drive-sales?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2214342",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T12:06:31-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 12:02:05",
    "publisher": "Zacks Investment Research",
    "title": "Mixed Q4 Earnings Report",
    "image": "https://images.financialmodelingprep.com/news/mixed-q4-earnings-report-20240123.jpg",
    "site": "zacks.com",
    "text": "Pre-market futures are mixed at this hour, coming off two strong trading days as Q4 earnings season begins to hit its stride. The Dow is -0.55% currently, while the S&P 500 and Nasdaq are +0.21% and +0.36%, respectively.",
    "url": "https://www.zacks.com/stock/news/2214340/mixed-q4-earnings-report?cid=CS-STOCKNEWSAPI-FT-economic_highlights-2214340",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T12:02:05-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 11:31:23",
    "publisher": "New York Post",
    "title": "J&J agrees to pay $700M to settle talc probes in 42 states",
    "image": "https://images.financialmodelingprep.com/news/jj-agrees-to-pay-700m-to-settle-talc-probes-20240123.jpg",
    "site": "nypost.com",
    "text": "J&J has maintained that its now-discontinued talc products are safe and do not cause cancer. It previously set aside $400 million to resolve state claims.",
    "url": "https://nypost.com/2024/01/23/business/jampj-agrees-to-pay-700m-to-settle-talc-probes-in-42-states/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T11:31:23-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 11:26:16",
    "publisher": "Zacks Investment Research",
    "title": "Q4 Earnings for J&J, Procter, GE & More",
    "image": "https://images.financialmodelingprep.com/news/q4-earnings-for-jj-procter-ge-more-20240123.jpg",
    "site": "zacks.com",
    "text": "Pre-market trading fortunes are mixed for this morning's reportees, including JNJ, PG, GE, MMM and DHI.",
    "url": "https://www.zacks.com/stock/news/2214313/q4-earnings-for-j-j-procter-ge-more?cid=CS-STOCKNEWSAPI-FT-ahead_of_wall_street-2214313",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T11:26:16-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 11:00:32",
    "publisher": "Zacks Investment Research",
    "title": "Johnson & Johnson (JNJ) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q4-earnings-taking-a-look-at-20240123.jpg",
    "site": "zacks.com",
    "text": "The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://www.zacks.com/stock/news/2214282/johnson-johnson-jnj-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2214282",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T11:00:32-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 10:10:32",
    "publisher": "Reuters",
    "title": "J&J agrees to resolve 42 U.S. states' talc investigations",
    "image": "https://images.financialmodelingprep.com/news/jj-agrees-to-resolve-42-us-states-talc-investigations-20240123.jpg",
    "site": "reuters.com",
    "text": "Johnson & Johnson on Tuesday said it had reached a tentative settlement to resolve probes by U.S. states into whether it misled consumers about the safety of its talc products, which thousands of lawsuits claim can cause cancer.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/jj-agrees-resolve-42-us-states-talc-investigations-2024-01-23/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T10:10:32-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 10:07:00",
    "publisher": "WSJ",
    "title": "Johnson & Johnson to Pay $700 Million to Settle Baby Powder Probe",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-pay-700-million-to-settle-baby-20240123.jpg",
    "site": "wsj.com",
    "text": "The agreement in principle addresses an investigation brought by more than 40 states into the marketing of its talcum-based baby powder.",
    "url": "https://www.wsj.com/articles/johnson-johnson-to-pay-700-million-to-settle-baby-powder-probe-307c4416",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T10:07:00-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 09:10:45",
    "publisher": "Zacks Investment Research",
    "title": "FDA Demands \"Boxed Warning\" to CAR T-Cell Therapy Labels",
    "image": "https://images.financialmodelingprep.com/news/fda-demands-boxed-warning-to-car-tcell-therapy-labels-20240123.jpg",
    "site": "zacks.com",
    "text": "The FDA directs companies like NVS, BMY, GILD and others to add \"boxed warning\" to the labels of their CAR T-cell immunotherapies after it identified adverse events.",
    "url": "https://www.zacks.com/stock/news/2214008/fda-demands-boxed-warning-to-car-t-cell-therapy-labels?cid=CS-STOCKNEWSAPI-FT-analyst_blog|industry_focus-2214008",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T09:10:45-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 08:16:23",
    "publisher": "Proactive Investors",
    "title": "Johnson & Johnson undershoots full-year earnings guidance",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-undershoots-fullyear-earnings-guidance-20240123.jpg",
    "site": "proactiveinvestors.com",
    "text": "New Jersey-based pharmaceutical giant Johnson & Johnson (NYSE:JNJ) hit top-line expectations in today's annual earnings call, but slightly undershot with its adjusted earnings results. The company reported a reported 6.5% year-on-year growth in sales of $85.2 billion, but the full-year earnings per share (EPS) depicted a different trend, decreasing by 15.3% to $5.20 a share.",
    "url": "https://www.proactiveinvestors.co.uk/companies/news/1039141?SNAPI",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T08:16:23-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 08:12:24",
    "publisher": "MarketBeat",
    "title": "Johnson & Johnson's stock price is at a critical turning point",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnsons-stock-price-is-at-a-critical-turning-20240123.jpg",
    "site": "marketbeat.com",
    "text": "Johnson & Johnson NYSE: JNJ had a solid quarter in Q4 despite the impacts of the Kenvue spin-off and the deleveraging of COVID-19 sales. However, little has emerged to catalyze the bulls, although ample news supports the stock price over the long term.",
    "url": "https://www.marketbeat.com/originals/johnson-and-johnsons-stock-price-is-at-a-critical-turning-point/?utm_source=snapi",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T08:12:24-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 08:02:43",
    "publisher": "Reuters",
    "title": "Johnson & Johnson still expects Carvykti to hit at least $5 bln peak sales -CFO",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-still-expects-carvykti-to-hit-at-least-20240123.jpg",
    "site": "reuters.com",
    "text": "Johnson & Johnson CFO Joseph Wolk said the drugmaker stills expects its cancer treatment Carvykti to reach peak sales of at least $5 billion, despite a new safety warning from the U.S. Food and Drug Administration.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-still-expects-carvykti-hit-least-5-bln-peak-sales-cfo-2024-01-23/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T08:02:43-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 07:20:35",
    "publisher": "Invezz",
    "title": "J&J Q4 earnings narrowly top expectations",
    "image": "https://images.financialmodelingprep.com/news/jj-q4-earnings-narrowly-top-expectations-20240123.jpg",
    "site": "invezz.com",
    "text": "Johnson & Johnson (NYSE: JNJ) just reported its financial results for the fourth quarter that slightly topped Street estimates. Its shares are roughly flat in premarket on Tuesday.",
    "url": "https://invezz.com/news/2024/01/23/jj-q4-earnings-narrowly-top-expectations/?utm_source=snapi",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T07:20:35-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 06:35:00",
    "publisher": "Market Watch",
    "title": "Johnson & Johnson Q4 earnings beat estimates amid strength in medtech",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-q4-earnings-beat-estimates-amid-strength-in-20240123.jpg",
    "site": "marketwatch.com",
    "text": "Johnson & Johnson JNJ, +0.49% said Tuesday it had net earnings of $4.132 billion, or $1.70 a share, for the fourth quarter, up from $3.227 billion, or $1.22 a share, in the year-earlier period. Adjusted per-share earnings came to $2.29, just ahead of the $2.28 FactSet consensus.",
    "url": "https://www.marketwatch.com/story/johnson-johnson-q4-earnings-beat-estimates-amid-strength-in-medtech-1803820f",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T06:35:00-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 06:23:46",
    "publisher": "Reuters",
    "title": "J&J beats profit estimates on pharmaceutical unit strength",
    "image": "https://images.financialmodelingprep.com/news/jj-beats-profit-estimates-on-pharmaceutical-unit-strength-20240123.jpg",
    "site": "reuters.com",
    "text": "Johnson & Johnson on Tuesday reported fourth-quarter profit above Wall Street expectations, helped by demand for its blockbuster psoriasis treatment Stelara and strength in its medical device unit.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/jj-beats-profit-estimates-pharmaceutical-unit-strength-2024-01-23/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T06:23:46-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 06:22:37",
    "publisher": "CNBC",
    "title": "Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-narrowly-tops-quarterly-estimates-as-pharmaceutical-medtech-20240123.jpeg",
    "site": "cnbc.com",
    "text": "The results come six months after J&J completed its spinoff of consumer health unit Kenvue, the company's biggest shake-up in its nearly 140-year history.",
    "url": "https://www.cnbc.com/2024/01/23/johnson-johnson-jnj-earnings-q4-2023.html",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T06:22:37-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-23 06:20:00",
    "publisher": "Business Wire",
    "title": "Johnson & Johnson Reports Q4 and Full-Year 2023 Results",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-reports-q4-and-fullyear-2023-results-20240123.jpg",
    "site": "businesswire.com",
    "text": "NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2023. “Johnson & Johnson's full year 2023 results reflect the breadth and competitiveness of our business and our relentless focus on delivering for patients,” said Joaquin Duato, Chairman and Chief Executive Officer. “We have entered 2024 from a position of strength, and I am confident in our ability to lead the next wave of health innovation.” Unless otherwise n.",
    "url": "https://www.businesswire.com/news/home/20240123117409/en/Johnson-Johnson-Reports-Q4-and-Full-Year-2023-Results/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-23T06:20:00-05:00",
    "date_et": "2024-01-23"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-24 22:20:06",
    "publisher": "Seeking Alpha",
    "title": "Johnson & Johnson: Balance Growth Between MedTech And Medicine, Initiate With A 'Buy'",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-balance-growth-between-medtech-and-medicine-initiate-20240124.jpg",
    "site": "seekingalpha.com",
    "text": "Johnson & Johnson reported strong Q4 FY23 results and reaffirmed guidance for FY24, exceeding expectations. The company's pharmaceutical business has the potential for 5-7% long-term growth, driven by novel therapies and made a strong presence in the oncology market. The MedTech sector is expected to have stable growth, with JNJ's robust procedure growth and product innovation contributing to expansion.",
    "url": "https://seekingalpha.com/article/4664820-johnson-and-johnson-stock-q4-earnings-balance-growth-medtech-medicine-initiate-buy",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-24T22:20:06-05:00",
    "date_et": "2024-01-24"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-24 21:22:00",
    "publisher": "Market Watch",
    "title": "Washington state reaches nearly $150 million settlement with Johnson & Johnson over opioid crisis",
    "image": "https://images.financialmodelingprep.com/news/washington-state-reaches-nearly-150-million-settlement-with-johnson-20240124.jpg",
    "site": "marketwatch.com",
    "text": "OLYMPIA, Wash. — The Washington state attorney general announced a $149.5 million settlement Wednesday with drug maker Johnson & Johnson, more than four years after the state sued the company over its role in the opioid addiction crisis.",
    "url": "https://www.marketwatch.com/story/washington-state-reaches-nearly-150-million-settlement-with-johnson-johnson-over-opioid-crisis-0003100f",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-24T21:22:00-05:00",
    "date_et": "2024-01-24"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-24 07:00:00",
    "publisher": "WSJ",
    "title": "J&J Can't Promise Wall Street No More Tears",
    "image": "https://images.financialmodelingprep.com/news/jj-cant-promise-wall-street-no-more-tears-20240124.jpg",
    "site": "wsj.com",
    "text": "Some investors struggle with owning the shares because of uncertainty over ongoing baby powder lawsuits.",
    "url": "https://www.wsj.com/articles/j-j-cant-promise-wall-street-no-more-tears-e9e3f0f2",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-24T07:00:00-05:00",
    "date_et": "2024-01-24"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-25 11:48:49",
    "publisher": "24/7 Wall Street",
    "title": "Just How Safe Is Abbott Labs Stock's Dividend?",
    "image": "https://images.financialmodelingprep.com/news/just-how-safe-is-abbott-labs-stocks-dividend-20240125.jpg",
    "site": "247wallst.com",
    "text": "A key component of income investing is a portfolio that includes safe dividends, those that are unlikely to shrink or disappear.",
    "url": "https://247wallst.com/investing/2024/01/25/just-how-safe-is-abbott-labs-stocks-dividend/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-25T11:48:49-05:00",
    "date_et": "2024-01-25"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-25 07:19:00",
    "publisher": "The Motley Fool",
    "title": "Better Dividend Stock to Buy Now: Johnson & Johnson vs. Verizon",
    "image": "https://images.financialmodelingprep.com/news/better-dividend-stock-to-buy-now-johnson-johnson-vs-20240125.jpg",
    "site": "fool.com",
    "text": "Johnson & Johnson reported strong earnings growth last year but its shares only offer a 3% dividend yield at recent prices. Verizon offers a big 6.3% dividend yield at recent prices but its bottom line shrank last year.",
    "url": "https://www.fool.com/investing/2024/01/25/better-dividend-stock-to-buy-now-johnson-johnson-v/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-25T07:19:00-05:00",
    "date_et": "2024-01-25"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-25 06:22:00",
    "publisher": "InvestorPlace",
    "title": "7 Dividend Stocks to Buy and Never Sell: January 2024 Edition",
    "image": "https://images.financialmodelingprep.com/news/7-dividend-stocks-to-buy-and-never-sell-january-2024-20240125.jpg",
    "site": "investorplace.com",
    "text": "One of the best ways to create wealth is finding the right dividend stocks to buy and hold. No other asset class has performed as well as buying equities, not gold, not bonds, not real estate.",
    "url": "https://investorplace.com/2024/01/7-dividend-stocks-to-buy-and-never-sell-january-2024-edition/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-25T06:22:00-05:00",
    "date_et": "2024-01-25"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-26 23:17:00",
    "publisher": "PRNewsWire",
    "title": "AMBRX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM",
    "image": "https://images.financialmodelingprep.com/news/ambrx-investor-alert-by-the-former-attorney-general-of-20240126.jpg",
    "site": "prnewswire.com",
    "text": "NEW ORLEANS , Jan. 26, 2024 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.",
    "url": "https://www.prnewswire.com/news-releases/ambrx-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick--foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-ambrx-biopharma-inc---amam-302046072.html",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-26T23:17:00-05:00",
    "date_et": "2024-01-26"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-26 17:03:52",
    "publisher": "InvestorPlace",
    "title": "Dividend Dynamos- 7 Stocks Delivering Consistent Cash Flow This Year",
    "image": "https://images.financialmodelingprep.com/news/dividend-dynamos-7-stocks-delivering-consistent-cash-flow-this-20240126.jpg",
    "site": "investorplace.com",
    "text": "Investing in the stock market isn't without the risks, but what if you could generate extra income from your investment? If you are a risk-averse investor like me and want to build a retirement portfolio, dividend stocks with consistent cash flow will appeal to you.",
    "url": "https://investorplace.com/2024/01/dividend-dynamos-7-stocks-delivering-consistent-cash-flow-this-year/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-26T17:03:52-05:00",
    "date_et": "2024-01-26"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-26 16:17:09",
    "publisher": "CNBC",
    "title": "Merck, Johnson & Johnson CEOs agree to testify in Senate hearing on high drug prices",
    "image": "https://images.financialmodelingprep.com/news/merck-johnson-johnson-ceos-agree-to-testify-in-senate-20240126.jpeg",
    "site": "cnbc.com",
    "text": "The CEOs of Merck, Johnson & Johnson and Bristol Myers Squibb will testify at the hearing on drug prices, Sen. Bernie Sanders said.",
    "url": "https://www.cnbc.com/2024/01/26/merck-jj-ceos-agree-to-testify-in-senate-hearing-on-drug-prices-.html",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-26T16:17:09-05:00",
    "date_et": "2024-01-26"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-26 10:31:23",
    "publisher": "Zacks Investment Research",
    "title": "Key Takeaways From JNJ's (JNJ) Q4 Earnings Presentation",
    "image": "https://images.financialmodelingprep.com/news/key-takeaways-from-jnjs-jnj-q4-earnings-presentation-20240126.jpg",
    "site": "zacks.com",
    "text": "J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.",
    "url": "https://www.zacks.com/stock/news/2216453/key-takeaways-from-jnj-s-jnj-q4-earnings-presentation?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_-_medical_sector-2216453",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-26T10:31:23-05:00",
    "date_et": "2024-01-26"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-27 10:15:00",
    "publisher": "The Motley Fool",
    "title": "Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson",
    "image": "https://images.financialmodelingprep.com/news/better-growth-stock-unitedhealth-group-vs-johnson-johnson-20240127.jpg",
    "site": "fool.com",
    "text": "UnitedHealth Group is an undervalued stock with some promising long-term growth prospects. Johnson & Johnson's business is leaner without its consumer health segment, and it has been focusing more on acquisitions of late.",
    "url": "https://www.fool.com/investing/2024/01/27/better-growth-stock-unitedhealth-group-vs-johnson/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-27T10:15:00-05:00",
    "date_et": "2024-01-27"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-28 08:00:01",
    "publisher": "CNBC",
    "title": "Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs",
    "image": "https://images.financialmodelingprep.com/news/big-pharma-is-at-a-crossroads-as-jj-merck-20240128.jpg",
    "site": "cnbc.com",
    "text": "Fast-approaching patent expirations will take a bite out of revenues and put the industry's top players in the hot seat over the next few years.",
    "url": "https://www.cnbc.com/2024/01/28/big-pharma-merck-bristol-myers-jj-prepare-to-lose-revenue.html",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-28T08:00:01-05:00",
    "date_et": "2024-01-28"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-28 01:26:31",
    "publisher": "Seeking Alpha",
    "title": "Johnson & Johnson: Positioned To Receive Benefits Of Heavy R&D Investments",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-positioned-to-receive-benefits-of-heavy-rd-20240128.jpg",
    "site": "seekingalpha.com",
    "text": "Johnson & Johnson is a multinational corporation in the healthcare and pharmaceutical sectors, showing indications of accelerated growth. J&J is currently the third largest player in the pharmaceutical industry, facing competition but with a low threat of substitutes. The FDA approval of Balversa and the acquisition of Ambrx Biopharma are expected to enhance sales growth and mitigate overall risk for J&J.",
    "url": "https://seekingalpha.com/article/4665579-johnson-and-johnson-positioned-receive-benefits-heavy-r-and-d-investments",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-28T01:26:31-05:00",
    "date_et": "2024-01-28"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-29 11:35:12",
    "publisher": "Reuters",
    "title": "Pharma industry to get US government price cut proposals by Thursday",
    "image": "https://images.financialmodelingprep.com/news/pharma-industry-to-get-us-government-price-cut-proposals-20240129.jpg",
    "site": "reuters.com",
    "text": "Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's first ever price negotiations.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-industry-get-us-government-price-cut-proposals-by-thursday-2024-01-29/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-29T11:35:12-05:00",
    "date_et": "2024-01-29"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-29 10:00:44",
    "publisher": "Zacks Investment Research",
    "title": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-jnj-is-a-trending-stock-facts-to-20240129.jpg",
    "site": "zacks.com",
    "text": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://www.zacks.com/stock/news/2216975/johnson-johnson-jnj-is-a-trending-stock-facts-to-know-before-betting-on-it?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2216975",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-29T10:00:44-05:00",
    "date_et": "2024-01-29"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-30 14:14:41",
    "publisher": "InvestorPlace",
    "title": "Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot",
    "image": "https://images.financialmodelingprep.com/news/buy-alert-3-healthcare-stocks-sitting-in-the-sweet-spot-20240130.jpg",
    "site": "investorplace.com",
    "text": "As investors, we are often looking to diversify our portfolios. Especially with the wild AI craze in the past year, many investors already hold positions in AI or other technology companies.",
    "url": "https://investorplace.com/2024/01/buy-alert-3-healthcare-stocks-sitting-in-the-sweet-spot/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-30T14:14:41-05:00",
    "date_et": "2024-01-30"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-30 13:52:54",
    "publisher": "CNBC",
    "title": "Healthy Returns: J&J, Merck and Bristol Myers Squibb are in the hot seat",
    "image": "https://images.financialmodelingprep.com/news/healthy-returns-jj-merck-and-bristol-myers-squibb-are-20240130.jpeg",
    "site": "cnbc.com",
    "text": "J&J, Merck and Bristol Myers Squibb face a pivotal few weeks ahead. Meanwhile, Apple will reportedly explore health applications for the Vision Pro headset.",
    "url": "https://www.cnbc.com/2024/01/30/healthy-returns-jj-merck-and-bristol-myers-squibb-in-the-hot-seat.html",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-30T13:52:54-05:00",
    "date_et": "2024-01-30"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-30 10:54:12",
    "publisher": "Stockmarketcom",
    "title": "3 Blue Chip Stocks To Watch Ahead Of February 2024",
    "image": "https://images.financialmodelingprep.com/news/3-blue-chip-stocks-to-watch-ahead-of-february-20240130.jpg",
    "site": "stockmarket.com",
    "text": "Blue chip stocks to watch in the stock market before February 2024.",
    "url": "https://stockmarket.com/featured/3-blue-chip-stocks-to-watch-ahead-of-february-2024-2024-01-30",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-30T10:54:12-05:00",
    "date_et": "2024-01-30"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-30 05:06:00",
    "publisher": "The Motley Fool",
    "title": "3 Perfect Stocks for Retirees to Buy Hand Over Fist in the New Bull Market",
    "image": "https://images.financialmodelingprep.com/news/3-perfect-stocks-for-retirees-to-buy-hand-over-20240130.jpg",
    "site": "fool.com",
    "text": "The benchmark S&P 500 recently climbed to a new all-time high, signaling without a shadow of a doubt that we're in a bull market. Bargains can still be found, even with the broader market hitting fresh highs.",
    "url": "https://www.fool.com/investing/2024/01/30/3-perfect-stocks-for-retirees-buy-new-bull-market/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-30T05:06:00-05:00",
    "date_et": "2024-01-30"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-31 11:56:52",
    "publisher": "InvestorPlace",
    "title": "The 7 Best Blue-Chip Stocks to Invest In for Big Gains in 2024",
    "image": "https://images.financialmodelingprep.com/news/the-7-best-bluechip-stocks-to-invest-in-for-20240131.jpg",
    "site": "investorplace.com",
    "text": "While technology stocks continue to drive the market higher, they are not the only game in town. Investors needn't invest only in semiconductor stocks to achieve big gains.",
    "url": "https://investorplace.com/2024/01/the-7-best-blue-chip-stocks-to-invest-in-for-big-gains-in-2024/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-31T11:56:52-05:00",
    "date_et": "2024-01-31"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-01-31 07:20:33",
    "publisher": "MarketBeat",
    "title": "4 med tech stocks with improving prognosis for 2024",
    "image": "https://images.financialmodelingprep.com/news/4-med-tech-stocks-with-improving-prognosis-for-2024-20240131.jpg",
    "site": "marketbeat.com",
    "text": "Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to dissipate, and the growth outlook was uncertain, leaving the market for their stock without a solid catalyst to drive it despite many trading at value levels and paying healthy dividends.",
    "url": "https://www.marketbeat.com/originals/4-med-techs-with-improving-prognosis-for-2024/?utm_source=snapi",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-01-31T07:20:33-05:00",
    "date_et": "2024-01-31"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-02-01 10:45:00",
    "publisher": "Seeking Alpha",
    "title": "MoneyShow's Best Investment Ideas For 2024: Part 6",
    "image": "https://images.financialmodelingprep.com/news/moneyshows-best-investment-ideas-for-2024-part-6-20240201.jpg",
    "site": "seekingalpha.com",
    "text": "MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income.",
    "url": "https://seekingalpha.com/article/4666718-moneyshow-best-investment-ideas-2024-part-6",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-02-01T10:45:00-05:00",
    "date_et": "2024-02-01"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-02-01 09:39:29",
    "publisher": "Forbes",
    "title": "Dow Stocks To Trade In February",
    "image": "https://images.financialmodelingprep.com/news/dow-stocks-to-trade-in-february-20240201.jpg",
    "site": "forbes.com",
    "text": "For this month, the cycle/relative strength concept is applied. First, the Dow Jones 30 stocks are ranked from the best performer to the worst by calculating the expected return in that month.",
    "url": "https://www.forbes.com/sites/greatspeculations/2024/02/01/dow-stocks-to-trade-in-february/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-02-01T09:39:29-05:00",
    "date_et": "2024-02-01"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-02-02 16:10:00",
    "publisher": "Business Wire",
    "title": "Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference",
    "image": "https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-raymond-james-45th-annual-20240202.jpg",
    "site": "businesswire.com",
    "text": "NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Raymond James 45th Annual Institutional Investors Conference on Tuesday, March 5th, at the JW Marriott Orlando Grande Lakes, Orlando, FL. Ahmet Tezel, Company Group Chairman, MedTech R&D will represent the Company in a session scheduled at 2:15 p.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at.",
    "url": "https://www.businesswire.com/news/home/20240202154233/en/Johnson-Johnson-to-Participate-in-the-Raymond-James-45th-Annual-Institutional-Investors-Conference/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-02-02T16:10:00-05:00",
    "date_et": "2024-02-02"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-02-03 09:00:00",
    "publisher": "Seeking Alpha",
    "title": "5 Relatively Secure And Cheap Dividend Stocks To Invest In - February 2024",
    "image": "https://images.financialmodelingprep.com/news/5-relatively-secure-and-cheap-dividend-stocks-to-invest-in-20240203.jpg",
    "site": "seekingalpha.com",
    "text": "This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields just over 3%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.",
    "url": "https://seekingalpha.com/article/4666385-5-relatively-secure-and-cheap-dividend-stocks-to-invest-in-february-2024",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-02-03T09:00:00-05:00",
    "date_et": "2024-02-03"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-02-04 11:54:47",
    "publisher": "Seeking Alpha",
    "title": "February Dogs Of The Dow: Buy 2, Watch 5",
    "image": "https://images.financialmodelingprep.com/news/february-dogs-of-the-dow-buy-2-watch-5-20240204.jpg",
    "site": "seekingalpha.com",
    "text": "\"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.” – DowJones & Co. The highest-yield 10 stocks are February's Dogs of the Dow: GS, JNJ, KO, CSCO, IBM, CVX, WBA, DOW, VZ, and MMM. They only averaged a 4.19% annual yield, as prices. Thirty Dow stocks represent nine of eleven sectors. DowJones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated February net-gains ranged 10.99%-23.09%, topped by MMM 2/2/24.",
    "url": "https://seekingalpha.com/article/4667411-february-dogs-of-the-dow-buy-2-watch-5",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-02-04T11:54:47-05:00",
    "date_et": "2024-02-04"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-02-04 08:20:00",
    "publisher": "The Motley Fool",
    "title": "2 Healthcare Dividend Kings to Buy and Hold Forever",
    "image": "https://images.financialmodelingprep.com/news/2-healthcare-dividend-kings-to-buy-and-hold-forever-20240204.jpg",
    "site": "fool.com",
    "text": "Abbott Laboratories and Johnson & Johnson have increased their payouts annually for 52 and 61 consecutive years, respectively. Both healthcare companies have long track records of important innovations and strong financial performances.",
    "url": "https://www.fool.com/investing/2024/02/04/2-healthcare-dividend-kings-to-buy-and-hold-foreve/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-02-04T08:20:00-05:00",
    "date_et": "2024-02-04"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-02-05 15:42:00",
    "publisher": "WSJ",
    "title": "J&J Accused of Mismanaging Its Employees' Drug Benefits",
    "image": "https://images.financialmodelingprep.com/news/jj-accused-of-mismanaging-its-employees-drug-benefits-20240205.jpg",
    "site": "wsj.com",
    "text": "The novel lawsuit by a J&J worker alleges employees overpaid for some drugs.",
    "url": "https://www.wsj.com/articles/j-j-accused-of-mismanaging-its-employees-drug-benefits-9da9a86e",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-02-05T15:42:00-05:00",
    "date_et": "2024-02-05"
  },
  {
    "symbol": "JNJ",
    "publishedDate": "2024-02-05 08:33:32",
    "publisher": "Reuters",
    "title": "J&J's immune disorder drug succeeds in studies",
    "image": "https://images.financialmodelingprep.com/news/jjs-immune-disorder-drug-succeeds-in-studies-20240205.jpg",
    "site": "reuters.com",
    "text": "Johnson & Johnson's experimental drug to treat two autoimmune disorders met the main goals in mid-stage and late-stage trials, the company said on Monday.",
    "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/jjs-immune-disorder-drug-succeeds-studies-2024-02-05/",
    "ticker": "JNJ",
    "event_date": "2024-01-23",
    "window_start": "2024-01-16",
    "window_end": "2024-02-06",
    "publishedDateET": "2024-02-05T08:33:32-05:00",
    "date_et": "2024-02-05"
  }
]